key: cord-0951609-nvrncl75
authors: Dimeglio, Chloé; Herin, Fabrice; Da-Silva, Isabelle; Porcheron, Marion; Martin-Blondel, Guillaume; Chapuy-Regaud, Sabine; Izopet, Jacques
title: Post-vaccination SARS-CoV-2 antibody kinetics and protection duration
date: 2021-11-27
journal: Clin Infect Dis
DOI: 10.1093/cid/ciab984
sha: 53ded8df2c40a75f35a47fb0c325aeab805d93b2
doc_id: 951609
cord_uid: nvrncl75

nan

A c c e p t e d M a n u s c r i p t Dear Editor, It will be difficult to mount an effective response to the SARS-CoV-2 pandemic without a clear understanding of the kinetics of the immune response to the virus [1, 2, 3] . A recent study looked at the kinetics of antibody avidity maturation in COVID-19 patients and showed that IgG avidity increased form 1-90 days associated with disease severity [4] . In a complementary way, another study in healthcare workers (HCWs) showed that a total antibody concentration greater than 141 BAU/ml provides 89.3% protection against SARS-CoV-2 infection [5] . In this study we determined the duration of protection conferred by the total antibodies taking into account the pre-vaccination infectious status and the waning humoral immunity.

We analyzed the total SARS-CoV-2 antibodies of 145 HCWs measured by ELISA (Wantai test, Wantai Biological Pharmacy Enterprise Co., Ltd, China) for 143 days (range 96-231) after their last injection of BNT162b2 vaccine. A total of 88 (60.7%) Elisa-negative HCWs and 57 (39.3%) infected HCWs were vaccinated and the subsequent decreases in antibody concentration were fitted to an exponential decay model. We observed a faster decrease for high initial total antibody concentrations at the peak. We segregated the vaccinated HCWs into three groups according to their total antibody concentrations one month after their second injection: <2000 BAU/ml, 2000 -10,000 BAU/ml, and > 10,000 BAU/ml. This study was approved by the French Research Ethics Committee Est-III (COVID BioToul, ID-RCB 2020-A01292-37, ClinicalTrials.gov Identifier: NCT04385108). A c c e p t e d M a n u s c r i p t 

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study

Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Avidity Maturation and Association with Disease Severity

Antibody titers and protection against a SARS-CoV-2 infection

The English text was edited by Dr Owen Parkes.

The authors declare no conflict of interest A c c e p t e d M a n u s c r i p t